Zenrelia™ (ilunocitinib tablets) offers veterinarians an option to relieve itching and inflammation in their canine patients. Andrew Rosenberg, DVM, DACVD, shares 5 key tips for integrating Zenrelia into your allergy management toolbox. Listen to the full Vet2Vet conversation below between Dr. Rosenberg and Cassi Fleming, MS, DVM.
Brought to you by Elanco Animal Health • ZenreliaForVets.com
1. Think Beyond the Clinical Signs
When a dog is severely itchy, everything suffers, including sleep, comfort and the human-animal bond. Using Zenrelia controls the itch, making it easier for families to reconnect and enjoy everyday life together.
2. Emphasize Simple Dosing
Once-daily dosing, without a need for loading or tapering, sets Zenrelia apart from other Janus kinase inhibitors. Simple and clear once daily dosing that does not change over time can help improve compliance.
3. Plan Around Vaccinations
Zenrelia affects the immune response, so it should not be given to patients concurrently with any vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia.
4. Highlight Individual Differences
Not all allergy patients are the same, even if they have similar clinical presentations. Each dog’s cytokine profile is unique, meaning it will respond differently to various therapies. Some patients who have failed similar therapies have had success with Zenrelia.
5. Monitor Success Comprehensively
Ask pet owners to monitor their pet’s quality of life rather than focusing only on the skin’s appearance. Improved sleep, reduced scratching, and better overall comfort are also important indicators of successful therapy. Objective tools like the pruritus visual analog scale (PVAS) can help clients track progress over time.
INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1-888-545-5973 or visit www.elancolabels.com/us/zenrelia.
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.
Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. ©2025 Elanco or its affiliates. PM-US-25-0931